Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798382 · ClinicalTrials.gov registry record · Phase 2
Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants
A Phase 2 study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT00798382: Completed Phase 2 study, sponsored by Abbott Nutrition.
NCT00798382 is a Phase 2 study that has completed, run by Abbott Nutrition. The registered enrollment target is 154 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00798382, a Phase 2 study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The objective of this study is to assess the comparative gastrointestinal (GI) tolerance of normal term infants to two experimental soy-based formulas, relative to a commercially available soy-based formula.
Interventions
- OTHER soy protein formula
- OTHER Commercially available soy formula
- OTHER Soy formula experimental #2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00798382 record still lists
NCT00798382 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 3 interventions - of which soy protein formula is the first listed.
NCT00798382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00798382 about?
NCT00798382 is a clinical study titled "Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants". The objective of this study is to assess the comparative gastrointestinal (GI) tolerance of normal term infants to two experimental soy-based formulas, relative to a commercially available soy-based formula.
What is the current status of trial NCT00798382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2008-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00798382?
The interventions under investigation include: soy protein formula (OTHER), Commercially available soy formula (OTHER), Soy formula experimental #2 (OTHER).
Who is sponsoring clinical trial NCT00798382?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00798382's enrollment target sits among peer trials
154 448th of 2000 higher than 1,552 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia